Companion Animal Therapeutics Market
Companion Animal Therapeutics Market Forecasts to 2034 - Global Analysis By Therapeutic Class (Parasiticides, Anti-Infectives, Dermatology Therapeutics, Pain and Anti-Inflammatory Drugs, Cardiovascular and Endocrine Drugs), Animal Type, Indication, Route of Administration, Distribution Channel, Prescription Status, End User, and By Geography
Market Dynamics:
Driver:
Expansion of veterinary treatment options and earlier disease diagnosis
Expanding veterinary treatment options and earlier disease diagnosis are increasing demand for companion animal therapeutics. Better screening, owner awareness and diagnostic access allow chronic and age-related conditions to be identified sooner, creating demand for parasiticides, anti-infectives, dermatology drugs, pain therapies and endocrine treatments. Veterinary referral networks and specialty practice growth support more targeted prescribing. As pets live longer and owners accept higher care standards, demand is likely to remain broad across acute, chronic and preventive treatment categories.
Restraint:
High treatment costs and species-specific approval requirements
High treatment costs can discourage owners from starting or continuing therapy, particularly for chronic conditions and multi-pet households. Species-specific approval requirements, limited label indications and regulatory variation increase development and market-access costs for suppliers. Clinics may face formulary constraints, reimbursement uncertainty and owner price sensitivity. These factors can slow adoption of newer therapies and widen gaps between specialist and general practice. Cost-effective dosing, clear value communication and appropriately approved products are needed to support sustainable access across species.
Opportunity:
Targeted therapies and improved access to veterinary medicines
Targeted therapies and improved access can expand companion animal treatment across specialty and primary-care settings. Practitioner partnerships, online pharmacies and clinic-led follow-up can improve adherence and owner understanding. Condition-specific products and clearer labeling can differentiate offerings and support appropriate use. There is also scope to serve underserved life stages and multi-pet households through coordinated veterinary, retail and digital channels. Providers that combine evidence, safety and convenient access can strengthen referrals, retention and responsible use beyond major urban centers.
Threat:
Regulatory hurdles, antimicrobial stewardship and safety risks
Regulatory hurdles, antimicrobial stewardship and safety risks can constrain companion animal therapeutics. Stricter prescribing controls, resistance concerns and adverse-event scrutiny may limit some anti-infective and chronic-use products. Manufacturing standards, ingredient availability and online-platform policies can affect quality and distribution. Competition from lower-priced substitutes and inconsistent claims may undermine trust. Companies need robust pharmacovigilance, traceable sourcing, responsible promotion and clear evidence to protect reputation, support veterinarians and maintain market access across jurisdictions.
Covid-19 Impact:
The COVID-19 pandemic disrupted veterinary appointments, specialist retail, travel and pet-care supply chains, while shifting more purchasing and advice-seeking online. Some owners postponed non-urgent services, but increased time at home and heightened attention to animal wellbeing supported demand for home-use products and digital support. Providers responded with e-commerce, teleconsultation and flexible scheduling. As restrictions eased, in-person services recovered, but demand for convenience and clear product information remained. The effect varied by market, depending on clinical need, discretionary spending and reliance on in-person experiences where available.
The Parasiticides segment is expected to be the largest during the forecast period
The Parasiticides segment is expected to account for a leading share of the companion animal therapeutics market during the forecast period. Its position reflects the relevance of this group to the addressable companion-animal population and the breadth of use across the market's principal therapeutic class applications. Established product availability, owner familiarity and professional recommendations support demand, while a wide range of care needs encourages repeat purchasing or service use. Market participants are expected to prioritize this segment through targeted product development, broader distribution and clearer use guidance.
The Other Companion Animals segment is expected to have the highest CAGR during the forecast period
The Other Companion Animals segment is expected to have the highest CAGR during the forecast period as providers expand targeted solutions and improve access through veterinary, specialist retail and digital channels. Demand is supported by growing awareness of the relevant need, improved product formulation or service delivery, and increased owner willingness to invest in tailored companion-animal care. As evidence, convenience and availability improve, this segment may attract new entrants and encourage established providers to broaden their portfolios.
Region with largest share:
North America is expected to account for a leading share of the companion animal therapeutics market, supported by high companion-animal ownership, comparatively developed veterinary infrastructure, established pet specialty retail and relatively high per-pet expenditure. The United States represents a major demand center because owners have access to veterinary clinics, online pet-care platforms and a broad selection of specialized products and services. Canada contributes through a mature pet-care ecosystem and established companion-animal health providers. Market adoption is also supported by insurance availability, consumer awareness and product innovation, although adoption differs by income, geography and veterinary access.
Region with highest CAGR:
Asia Pacific is expected to exhibit strong growth in the companion animal therapeutics market as pet ownership, urban household formation, veterinary service availability and organized pet retail expand across major markets. China, Japan, South Korea, India and Australia offer different adoption pathways, reflecting differences in purchasing power, veterinary infrastructure, product regulation and the role of digital commerce. Growing awareness of preventive care and rising demand for premium companion-animal products are likely to support market development. Expansion will depend on localized products, professional education and compliance with national animal-health and consumer-protection requirements.
Key players in the market
Some of the key players in the Global Companion Animal Therapeutics Market include Zoetis Inc., Elanco Animal Health, Merck Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Virbac, Dechra Pharmaceuticals PLC, Vetoquinol, Norbrook Laboratories, Bimeda, Phibro Animal Health Corporation, Kyoritsu Seiyaku Corporation, Sichuan Yuanda Shuyang Pharmaceutical, Chanelle Pharma, KRKA d.d., IDEXX Laboratories, Inc., Covetrus, Inc., Ourofino Saúde Animal.
Key Developments:
In July 2026, Royal Canin (Mars Petcare) launched its first fresh, fully cooked veterinary diet portfolio for dogs, addressing selected gastrointestinal needs, food sensitivities and reduced appetite through veterinarian-exclusive nutrition.
In May 2026, Elanco Animal Health began a phased U.S. launch of Befrena, an anti-IL-31 monoclonal antibody injection for dogs with allergic and atopic dermatitis.
In February 2026, Merck Animal Health announced FDA approval of NUMELVI, a second-generation JAK inhibitor for control of pruritus associated with allergic dermatitis in dogs.
Therapeutic Class Covered:
• Parasiticides
• Anti-Infectives
• Dermatology Therapeutics
• Pain and Anti-Inflammatory Drugs
• Cardiovascular and Endocrine Drugs
Animal Types Covered:
• Dogs
• Cats
• Equine Companion Animals
• Other Companion Animals
Indications Covered:
• Dermatology
• Orthopedic and Pain Conditions
• Oncology
• Cardiometabolic Disorders
• Infectious Diseases
Route of Administration Covered:
• Oral
• Injectable
• Topical
• Otic and Ophthalmic
Distribution Channels Covered:
• Veterinary Hospitals and Clinics
• Veterinary Distributors
• Retail and Online Veterinary Pharmacies
• Specialty Animal Health Platforms
Prescription Status Covered:
• Prescription-Only Therapeutics
• Over-the-Counter Veterinary Medicines
• Specialty and Biologic Therapies
End Users Covered:
• General Veterinary Clinics
• Specialty Veterinary Hospitals
• Veterinary Pharmacies and Distributors
• Animal Welfare and Shelter Programs
Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa
What our report offers:
• Market share assessments for regional and country-level segments
• Strategic recommendations for new entrants
• Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
• Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
• Strategic recommendations for key business segments based on market estimations
• Competitive landscape mapping and assessment of key industry trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends and assessment of the latest technological advancements
Free Customization Offerings:
All customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 Research Framework
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 Market Dynamics and Trend Analysis
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 Competitive and Strategic Assessment
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 Global Companion Animal Therapeutics Market, By Therapeutic Class
5.1 Parasiticides
5.2 Anti-Infectives
5.3 Dermatology Therapeutics
5.4 Pain and Anti-Inflammatory Drugs
5.5 Cardiovascular and Endocrine Drugs
6 Global Companion Animal Therapeutics Market, By Animal Type
6.1 Dogs
6.2 Cats
6.3 Equine Companion Animals
6.4 Other Companion Animals
7 Global Companion Animal Therapeutics Market, By Indication
7.1 Dermatology
7.2 Orthopedic and Pain Conditions
7.3 Oncology
7.4 Cardiometabolic Disorders
7.5 Infectious Diseases
8 Global Companion Animal Therapeutics Market, By Route of Administration
8.1 Oral
8.2 Injectable
8.3 Topical
8.4 Otic and Ophthalmic
9 Global Companion Animal Therapeutics Market, By Distribution Channel
9.1 Veterinary Hospitals and Clinics
9.2 Veterinary Distributors
9.3 Retail and Online Veterinary Pharmacies
9.4 Specialty Animal Health Platforms
10 Global Companion Animal Therapeutics Market, By Prescription Status
10.1 Prescription-Only Therapeutics
10.2 Over-the-Counter Veterinary Medicines
10.3 Specialty and Biologic Therapies
11 Global Companion Animal Therapeutics Market, By End User
11.1 General Veterinary Clinics
11.2 Specialty Veterinary Hospitals
11.3 Veterinary Pharmacies and Distributors
11.4 Animal Welfare and Shelter Programs
12 Global Companion Animal Therapeutics Market, By Geography
12.1 North America
12.1.1 United States
12.1.2 Canada
12.1.3 Mexico
12.2 Europe
12.2.1 United Kingdom
12.2.2 Germany
12.2.3 France
12.2.4 Italy
12.2.5 Spain
12.2.6 Netherlands
12.2.7 Belgium
12.2.8 Sweden
12.2.9 Switzerland
12.2.10 Poland
12.2.11 Rest of Europe
12.3 Asia Pacific
12.3.1 China
12.3.2 Japan
12.3.3 India
12.3.4 South Korea
12.3.5 Australia
12.3.6 Indonesia
12.3.7 Thailand
12.3.8 Malaysia
12.3.9 Singapore
12.3.10 Vietnam
12.3.11 Rest of Asia Pacific
12.4 South America
12.4.1 Brazil
12.4.2 Argentina
12.4.3 Colombia
12.4.4 Chile
12.4.5 Peru
12.4.6 Rest of South America
12.5 Rest of the World (RoW)
12.5.1 Middle East
12.5.1.1 Saudi Arabia
12.5.1.2 United Arab Emirates
12.5.1.3 Qatar
12.5.1.4 Israel
12.5.1.5 Rest of Middle East
12.5.2 Africa
12.5.2.1 South Africa
12.5.2.2 Egypt
12.5.2.3 Morocco
12.5.2.4 Rest of Africa
13 Strategic Market Intelligence
13.1 Industry Value Network and Supply Chain Assessment
13.2 White-Space and Opportunity Mapping
13.3 Product Evolution and Market Life Cycle Analysis
13.4 Channel, Distributor, and Go-to-Market Assessment
14 Industry Developments and Strategic Initiatives
14.1 Mergers and Acquisitions
14.2 Partnerships, Alliances, and Joint Ventures
14.3 New Product Launches and Certifications
14.4 Capacity Expansion and Investments
14.5 Other Strategic Initiatives
15 Company Profiles
15.1 Zoetis Inc.
15.2 Elanco Animal Health
15.3 Merck Animal Health
15.4 Boehringer Ingelheim Animal Health
15.5 Ceva Santé Animale
15.6 Virbac
15.7 Dechra Pharmaceuticals PLC
15.8 Vetoquinol
15.9 Norbrook Laboratories
15.10 Bimeda
15.11 Phibro Animal Health Corporation
15.12 Kyoritsu Seiyaku Corporation
15.13 Sichuan Yuanda Shuyang Pharmaceutical
15.14 Chanelle Pharma
15.15 KRKA d.d.
15.16 IDEXX Laboratories, Inc.
15.17 Covetrus, Inc.
15.18 Ourofino Saúde Animal
List of Tables
1 Global Companion Animal Therapeutics Market Outlook, By Region (2023–2034) ($MN)
2 Global Companion Animal Therapeutics Market Outlook, By Therapeutic Class (2023–2034) ($MN)
3 Global Companion Animal Therapeutics Market Outlook, By Parasiticides (2023–2034) ($MN)
4 Global Companion Animal Therapeutics Market Outlook, By Anti-Infectives (2023–2034) ($MN)
5 Global Companion Animal Therapeutics Market Outlook, By Dermatology Therapeutics (2023–2034) ($MN)
6 Global Companion Animal Therapeutics Market Outlook, By Pain and Anti-Inflammatory Drugs (2023–2034) ($MN)
7 Global Companion Animal Therapeutics Market Outlook, By Cardiovascular and Endocrine Drugs (2023–2034) ($MN)
8 Global Companion Animal Therapeutics Market Outlook, By Animal Type (2023–2034) ($MN)
9 Global Companion Animal Therapeutics Market Outlook, By Dogs (2023–2034) ($MN)
10 Global Companion Animal Therapeutics Market Outlook, By Cats (2023–2034) ($MN)
11 Global Companion Animal Therapeutics Market Outlook, By Equine Companion Animals (2023–2034) ($MN)
12 Global Companion Animal Therapeutics Market Outlook, By Other Companion Animals (2023–2034) ($MN)
13 Global Companion Animal Therapeutics Market Outlook, By Indication (2023–2034) ($MN)
14 Global Companion Animal Therapeutics Market Outlook, By Dermatology (2023–2034) ($MN)
15 Global Companion Animal Therapeutics Market Outlook, By Orthopedic and Pain Conditions (2023–2034) ($MN)
16 Global Companion Animal Therapeutics Market Outlook, By Oncology (2023–2034) ($MN)
17 Global Companion Animal Therapeutics Market Outlook, By Cardiometabolic Disorders (2023–2034) ($MN)
18 Global Companion Animal Therapeutics Market Outlook, By Infectious Diseases (2023–2034) ($MN)
19 Global Companion Animal Therapeutics Market Outlook, By Route of Administration (2023–2034) ($MN)
20 Global Companion Animal Therapeutics Market Outlook, By Oral (2023–2034) ($MN)
21 Global Companion Animal Therapeutics Market Outlook, By Injectable (2023–2034) ($MN)
22 Global Companion Animal Therapeutics Market Outlook, By Topical (2023–2034) ($MN)
23 Global Companion Animal Therapeutics Market Outlook, By Otic and Ophthalmic (2023–2034) ($MN)
24 Global Companion Animal Therapeutics Market Outlook, By Distribution Channel (2023–2034) ($MN)
25 Global Companion Animal Therapeutics Market Outlook, By Veterinary Hospitals and Clinics (2023–2034) ($MN)
26 Global Companion Animal Therapeutics Market Outlook, By Veterinary Distributors (2023–2034) ($MN)
27 Global Companion Animal Therapeutics Market Outlook, By Retail and Online Veterinary Pharmacies (2023–2034) ($MN)
28 Global Companion Animal Therapeutics Market Outlook, By Specialty Animal Health Platforms (2023–2034) ($MN)
29 Global Companion Animal Therapeutics Market Outlook, By Prescription Status (2023–2034) ($MN)
30 Global Companion Animal Therapeutics Market Outlook, By Prescription-Only Therapeutics (2023–2034) ($MN)
31 Global Companion Animal Therapeutics Market Outlook, By Over-the-Counter Veterinary Medicines (2023–2034) ($MN)
32 Global Companion Animal Therapeutics Market Outlook, By Specialty and Biologic Therapies (2023–2034) ($MN)
33 Global Companion Animal Therapeutics Market Outlook, By End User (2023–2034) ($MN)
34 Global Companion Animal Therapeutics Market Outlook, By General Veterinary Clinics (2023–2034) ($MN)
35 Global Companion Animal Therapeutics Market Outlook, By Specialty Veterinary Hospitals (2023–2034) ($MN)
36 Global Companion Animal Therapeutics Market Outlook, By Veterinary Pharmacies and Distributors (2023–2034) ($MN)
37 Global Companion Animal Therapeutics Market Outlook, By Animal Welfare and Shelter Programs (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.